Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.
Cancer research • Vol. 76, Issue 5 • 2016
Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
Leukemia • Vol. 30, Issue 1 • 2016
Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models.
Molecular cancer therapeutics • Vol. 13, Issue 5 • 2014
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
Journal of medicinal chemistry • Vol. 57, Issue 3 • 2014